Sonoma Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	17.72	14.29	12.74	13.27	12.63	18.63
Revenue Growth (YoY)	26.83%	12.20%	-4.05%	5.10%	-32.21%	3.91%
Cost of Revenue	10.96	8.82	7.99	8.8	8.64	12.07
Gross Profit	6.76	5.47	4.75	4.48	3.99	6.56
Selling, General & Admin	7.39	7.36	7.58	8.84	9.76	9.45
Research & Development	2.14	1.81	1.87	0.21	0.13	0.56
Operating Expenses	9.53	9.18	9.45	9.05	9.88	10.01
Operating Income	-2.77	-3.71	-4.7	-4.57	-5.89	-3.45
Interest Expense	-	-	-	-	-0.01	-
Interest & Investment Income	-	-	-	-	-	0
Currency Exchange Gain (Loss)	0.24	0.24	-0.83	-0.69	-0.58	-0.69
Other Non Operating Income (Expenses)	-0.93	0.56	0.5	0.08	0.19	0.1
EBT Excluding Unusual Items	-3.45	-2.91	-5.03	-5.18	-6.29	-4.04
Gain (Loss) on Sale of Assets	-	-	-	-	0.15	0.14
Other Unusual Items	-	-	-	-	0.72	-
Pretax Income	-3.45	-2.91	-5.03	-5.18	-5.42	-3.9
Income Tax Expense	-0.08	0.55	-0.2	-0.03	-0.33	0.71
Earnings From Continuing Operations	-3.37	-3.46	-4.84	-5.15	-5.09	-4.62
Earnings From Discontinued Operations	-	-	-	-	-	0.67
Net Income	-3.37	-3.46	-4.84	-5.15	-5.09	-3.95
Net Income to Common	-3.37	-3.46	-4.84	-5.15	-5.09	-3.95
Shares Outstanding (Basic)	2	1	0	0	0	0
Shares Outstanding (Diluted)	2	1	0	0	0	0
Shares Change (YoY)	60.61%	172.75%	168.12%	27.93%	32.92%	35.14%
EPS (Basic)	-2.04	-2.79	-10.63	-30.35	-38.34	-39.58
EPS (Diluted)	-2.04	-2.79	-10.63	-30.35	-38.34	-39.58
Free Cash Flow	-3.72	-0.17	-2.4	-6.42	-4.39	-3.56
Free Cash Flow Per Share	-2.25	-0.14	-5.28	-37.84	-33.06	-35.64
Gross Margin	38.16%	38.25%	37.26%	33.73%	31.62%	35.21%
Operating Margin	-15.61%	-25.97%	-36.91%	-34.43%	-46.62%	-18.51%
Profit Margin	-19.02%	-24.20%	-37.97%	-38.81%	-40.28%	-21.20%
Free Cash Flow Margin	-20.98%	-1.18%	-18.85%	-48.38%	-34.72%	-19.09%
EBITDA	-2.63	-3.57	-4.53	-4.45	-5.7	-3.22
EBITDA Margin	-14.84%	-25.00%	-35.53%	-33.49%	-45.15%	-17.30%
D&A For EBITDA	0.14	0.14	0.18	0.13	0.19	0.23
EBIT	-2.77	-3.71	-4.7	-4.57	-5.89	-3.45
EBIT Margin	-15.61%	-25.97%	-36.91%	-34.43%	-46.62%	-18.51%
Advertising Expenses	-	0.19	0.16	0.16	0.09	0.04

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q